Lopressor/use in specific populations: Difference between revisions

Latest revision as of 03:51, 22 July 2014

Redirect to:

@@ Line 1: / Line 1: @@
-__NOTOC__
+#REDIRECT [[Metoprolol tartrate#Use in Specific Populations]]
-{{Metoprolol}}
-{{CMG}}
-==Use in Special Population==
-====Pediatric patients====
-No pediatric studies have been performed. The safety and efficacy of Lopressor in pediatric patients have not been established.
-====Renal impairment====
-No dose adjustment of Lopressor is required in patients with renal impairment.
-====Hepatic impairment====
-Lopressor blood levels are likely to increase substantially in patients with hepatic impairment. Therefore, Lopressor should be initiated at low doses with cautious gradual dose titration according to clinical response.
-====Geriatric patients (>65 years)====
-In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
-==References==
-{{Reflist}}
-{{FDA}}
-[[Category:Drugs]]
-[[Category:Cardiovascular Drugs]]
-[[Category:Beta blockers]]